U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Hybridomas Secreting Novel Monoclonal Antibodies Against the Nucleoprotein Of Influenza Virus
  1. Licensing and Collaboration Opportunities

Hybridomas Secreting Novel Monoclonal Antibodies Against the Nucleoprotein Of Influenza Virus

Download the Abstract (PDF - 0.85MB)

Technology Summary

Influenza A viruses pose a serious threat to public health. The nucleoprotein (NP) of an influenza virus is a highly conserved protein involved in the transcription, replication and packaging of the viral genome, influencing the virulence of the virus within the host.

This invention is a hybridoma that secrets monoclonal antibodies that can broadly-react against the NP of influenza viruses. The antibodies, designated G20, A40 and A60, were specifically raised against the NP of the H3N2 virus A/Minnesota/11/2010.

Potential Commercial Applications Competitive Advantages
  • Research tool
  • Development of a clinical diagnostic for rapid detection of influenza virus infection
  • Broadly react with the NP of all tested subtypes of Influenza A viruses
  • Antibody G20 has strong reactivity with the NP of equine H3N8 virus

Development Stage: Research reagent

Inventors: Hongquan Wan

Product Area:  Bioassay, diagnostics, vaccine

FDA Reference No:E-2018-007  

Licensing Contact:
Bill Ronnenberg, MS, JD/MIP
FDA Technology Transfer Program
Email: [email protected]
Phone: 240-402-4561

Back to Top